Clinical Chemistry and Laboratory Medicine (CCLM) · 2022 · 44 citations · 45 references
PharmacyBiochemistryGeriatric MedicineAgingClinical BiochemistryGlial BiologyBioanalytical Method ValidationBiomarker AnalysisClinical AnalysisNonparametric Quantile RegressionPreanalytical VariabilityProtein Biomarker QuantificationQuantile RegressionQuantitative Assay ValidationReference BiomarkersReference Interval DeterminationSample Stability Assessment
OBJECTIVES: Glial fibrillary acidic protein (GFAP) is a promising biomarker that could potentially contribute to diagnosis and prognosis in neurological diseases. The biomarker is approaching clinical use but the reference interval for serum GFAP remains to be established, and knowledge about the effect of preanalytical factors is also limited. METHODS: Serum samples from 371 apparently healthy reference subjects, 21-90 years of age, were measured by a single-molecule array (Simoa) assay. Continuous reference intervals were modelled using non-parametric quantile regression and compared with traditional age-partitioned non-parametric reference intervals established according to the Clinical and Laboratory Standards Institute (CLSI) guideline C28-A3. The following preanalytical conditions were also examined: stability in whole blood at room temperature (RT), stability in serum at RT and -20 °C, repeated freeze-thaw cycles, and haemolysis. RESULTS: The continuous reference interval showed good overall agreement with the traditional age-partitioned reference intervals of 25-136 ng/L, 34-242 ng/L, and 5-438 ng/L for the age groups 20-39, 40-64, and 65-90 years, respectively. Both types of reference intervals showed increasing levels and variability of serum GFAP with age. In the preanalytical tests, the mean changes from baseline were 2.3% (95% CI: -2.4%, 6.9%) in whole blood after 9 h at RT, 3.1% (95% CI: -4.5%, 10.7%) in serum after 7 days at RT, 10.4% (95% CI: -6.0%, 26.8%) in serum after 133 days at -20 °C, and 10.4% (95% CI: 9.5%, 11.4%) after three freeze-thaw cycles. CONCLUSIONS: The study establishes age-dependent reference ranges for serum GFAP in adults and demonstrates overall good stability of the biomarker.
45
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
Shorena Janelidze, Ruben Smith, Niklas Mattsson et al. · Brain · 2021 · 587 citations · Full text
Medicine, Neurology, Neuroscience +17
β-Amyloid burden in healthy aging
Karen M. Rodrigue, Kristen M. Kennedy, Michael D. Devous et al. · Neurology · 2012 · 423 citations · Full text
Medicine, Neurology, Neuroscience +17
Serum GFAP as a biomarker for disease severity in multiple sclerosis
Ahmed Abdelhak, André Huss, Jan Kassubek et al. · Scientific Reports · 2018 · 285 citations · Full text
Medicine, Neurology, Neuroscience +17